Stockscreener 앱 받기
1.57
1.29%
0.02
전일 마감가:
$1.55
열려 있는:
$1.55
하루 거래량:
32,596
Relative Volume:
0.34
시가총액:
$82.39M
수익:
-
순이익/손실:
$-4.61M
주가수익비율:
-12.52
EPS:
-0.1254
순현금흐름:
$-3.10M
1주 성능:
-5.99%
1개월 성능:
-4.27%
6개월 성능:
-5.42%
1년 성능:
-30.22%
1일 변동 폭
$1.52
$1.595
1주일 범위
$1.51
$1.669
52주 변동 폭
$1.3401
$3.20
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.57 | 79.77M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Piper Sandler | Overweight |
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
OKYO (OKYO) Watch: Declines 0.33% to $1.51 on the Day; Key Range: the Supplied Trading Band Runs From $1.43 to $1.59 for the Current SessionCounter Trend Trade - vinanet.vn
OKYO Pharma (OKYO) Edges Up 1.33% to $1.52 as Support at $1.44 HoldsCalendar Spread Trade - vinanet.vn
Short Interest in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Expands By 223.4% - MarketBeat
OKYO Pharma (NASDAQ: OKYO) updates 20-F to add clawback policy exhibit - stocktitan.net
OKYO Pharma (OKYO) director buys 5,000 shares in open market - Stock Titan
OKYO Pharma (OKYO) Slips 2.6% to $1.49, Testing Key Support at $1.42AD Line Divergence - dars.gov.et
Price to sales forward of OKYO Pharma Limited – NASDAQ:OKYO - tradingview.com
OKYO Pharma (OKYO) Expected to Post Quarterly Earnings on Monday - MarketBeat
Form 4 OKYO Pharma Ltd For: 29 July By Investing.com - Investing.com Canada
OKYO Pharma CSO buys shares - Proactive financial news
OKYO Pharma CSO purchases additional shares at $1.49 By Investing.com - Investing.com Nigeria
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CSO boosts stake, plans Phase 3 NCP trial - Stock Titan
OKYO Pharma scientist's holdings reach 20,030 shares after purchase - Stock Titan
OKYO Pharma Ltd (OKYO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OKYO Pharma to participate in BTIG Biotechnology Conference 2026 - Proactive financial news
OKYO Pharma Ltd (OKYO) Cash Flow - TradingKey
OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans - simplywall.st
OKYO Pharma to Participate in BTIG Biotechnology Conference 2026 - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) plans Phase 3 NCP trial, joins BTIG conference - Stock Titan
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026 - GlobeNewswire
OKYO Pharma Ltd (OKYO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OKYO Pharma Ltd (OKYO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OKYO Pharma Ltd (OKYO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
OKYO Pharma Ltd (OKYO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OKYO Pharma Ltd (OKYO) Institutional Confidence - TradingKey
OKYO Pharma Ltd (OKYO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OKYO Pharma Limited Revenue Breakdown – GETTEX:OK11 - TradingView
OKYO|OKYO Pharma Ltd|Price:1.530|Chg%:+0.020 - TradingKey
TradingKey - TradingKey
OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain - Ophthalmology Times Europe
Form 4 OKYO Pharma Ltd For: 24 July By Investing.com - Investing.com South Africa
OKYO Pharma Announces Purchase of Shares by Director - The Manila Times
OKYO Pharma (OKYO) grants 3,500 shares to chief development officer - Stock Titan
OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch - Kalkine Media
OKYO Pharma director buys 5,000 shares at $1.48, increasing his stake to 35,201 shares. - Pluang
OKYO Pharma Director John Brancaccio Purchases 5,000 Shares on Nasdaq - Quiver Quantitative
OKYO Pharma (Nasdaq: OKYO) director ups stake with 5,000-share purchase - Stock Titan
OKYO Pharma CEO purchases 15,000 shares at $1.54 each - Investing.com
OKYO Pharma CEO purchases 15,000 shares at $1.54 each By Investing.com - Investing.com South Africa
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer - The Manila Times
OKYO Pharma (Nasdaq: OKYO) CEO purchases 15,000 company shares - Stock Titan
OKYO Pharma says CEO purchased 15,000 shares - Proactive financial news
OKYO Pharma executive purchases 3,500 shares at $1.40 each By Investing.com - Investing.com Australia
OKYO Pharma grants CMO 20,000 common shares | OKYO Insider Trading - Stock Titan
OKYO Pharma Chairman Boosts Stake to Over 20% Ahead of Phase 3 Trial - TipRanks
OKYO Pharma Chairman buys 22,500 shares, raisin... - Pluang
OKYO Pharma (Nasdaq: OKYO) chair buys more shares, now owns 20.55% - Stock Titan
OKYO Pharma LTD - Via Ritzau
OKYO Pharma executive purchases 3,500 shares at $1.40 each - Investing.com India
OKYO Pharma CMO purchases 20,000 shares at $1.40 each By Investing.com - Investing.com South Africa
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):